325 related articles for article (PubMed ID: 35964287)
1. PD-L1 testing by immunohistochemistry in immuno-oncology.
Vranic S; Gatalica Z
Biomol Biomed; 2023 Feb; 23(1):15-25. PubMed ID: 35964287
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 as a biomarker of response to immune-checkpoint inhibitors.
Doroshow DB; Bhalla S; Beasley MB; Sholl LM; Kerr KM; Gnjatic S; Wistuba II; Rimm DL; Tsao MS; Hirsch FR
Nat Rev Clin Oncol; 2021 Jun; 18(6):345-362. PubMed ID: 33580222
[TBL] [Abstract][Full Text] [Related]
3. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Paver EC; Cooper WA; Colebatch AJ; Ferguson PM; Hill SK; Lum T; Shin JS; O'Toole S; Anderson L; Scolyer RA; Gupta R
Pathology; 2021 Feb; 53(2):141-156. PubMed ID: 33388161
[TBL] [Abstract][Full Text] [Related]
4. Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP).
Cheung CC; Barnes P; Bigras G; Boerner S; Butany J; Calabrese F; Couture C; Deschenes J; El-Zimaity H; Fischer G; Fiset PO; Garratt J; Geldenhuys L; Gilks CB; Ilie M; Ionescu D; Lim HJ; Manning L; Mansoor A; Riddell R; Ross C; Roy-Chowdhuri S; Spatz A; Swanson PE; Tron VA; Tsao MS; Wang H; Xu Z; Torlakovic EE;
Appl Immunohistochem Mol Morphol; 2019; 27(10):699-714. PubMed ID: 31584451
[TBL] [Abstract][Full Text] [Related]
5. Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Hersom M; Jørgensen JT
Ther Drug Monit; 2018 Feb; 40(1):9-16. PubMed ID: 29084031
[TBL] [Abstract][Full Text] [Related]
6. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
Gadgeel S; Hirsch FR; Kerr K; Barlesi F; Park K; Rittmeyer A; Zou W; Bhatia N; Koeppen H; Paul SM; Shames D; Yi J; Matheny C; Ballinger M; McCleland M; Gandara DR
Clin Lung Cancer; 2022 Jan; 23(1):21-33. PubMed ID: 34226144
[TBL] [Abstract][Full Text] [Related]
7. PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay.
Cimadamore A; Massari F; Santoni M; Lopez-Beltran A; Cheng L; Scarpelli M; Montironi R; Moch H
Curr Drug Targets; 2020; 21(16):1664-1671. PubMed ID: 32208115
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 and beyond: Immuno-oncology in cytopathology.
Iaccarino A; Salatiello M; Migliatico I; De Luca C; Gragnano G; Russo M; Bellevicine C; Malapelle U; Troncone G; Vigliar E
Cytopathology; 2021 Sep; 32(5):596-603. PubMed ID: 33955097
[TBL] [Abstract][Full Text] [Related]
9. Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer.
Hecking T; Thiesler T; Halbe J; Otten L; Recker F; Gevensleben H; Müller T; Schiller C; Egger EK; Fimmers R; Stope MB; Kristiansen G; Mustea A
Anticancer Res; 2022 Mar; 42(3):1367-1376. PubMed ID: 35220229
[TBL] [Abstract][Full Text] [Related]
10. Companion Diagnostics: Lessons Learned and the Path Forward From the Programmed Death Ligand-1 Rollout.
Willis JE; Eyerer F; Walk EE; Vasalos P; Bradshaw G; Yohe SL; Laser JS
Arch Pathol Lab Med; 2023 Jan; 147(1):62-70. PubMed ID: 35472701
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare.
Zouein J; Kesrouani C; Kourie HR
Immunotherapy; 2021 Aug; 13(12):1053-1065. PubMed ID: 34190579
[TBL] [Abstract][Full Text] [Related]
12. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers.
Tang Q; Chen Y; Li X; Long S; Shi Y; Yu Y; Wu W; Han L; Wang S
Front Immunol; 2022; 13():964442. PubMed ID: 36177034
[TBL] [Abstract][Full Text] [Related]
13. An update on companion and complementary diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC.
Jørgensen JT
Expert Rev Mol Diagn; 2021 May; 21(5):445-454. PubMed ID: 33896308
[No Abstract] [Full Text] [Related]
14. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
[TBL] [Abstract][Full Text] [Related]
15. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics.
Twomey JD; Zhang B
AAPS J; 2021 Mar; 23(2):39. PubMed ID: 33677681
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer.
Sholl LM
Mod Pathol; 2022 Jan; 35(Suppl 1):66-74. PubMed ID: 34608245
[TBL] [Abstract][Full Text] [Related]
17. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
Rizzo A; Mollica V; Massari F
Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
[TBL] [Abstract][Full Text] [Related]
18. [Current landscape of biomarker development for immune checkpoint inhibitors targeting PD-1/PD-L1 pathway in oncology].
Chaput L; Jordheim LP
Therapie; 2021; 76(6):597-615. PubMed ID: 34332787
[TBL] [Abstract][Full Text] [Related]
19. Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
Uruga H; Mino-Kenudson M
Virchows Arch; 2021 Jan; 478(1):31-44. PubMed ID: 33486574
[TBL] [Abstract][Full Text] [Related]
20. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis.
Wang YN; Lee HH; Hsu JL; Yu D; Hung MC
J Biomed Sci; 2020 Jul; 27(1):77. PubMed ID: 32620165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
